全球急性肌張力不全症市場：按藥物類別、年齡層、分銷管道和地區分類。

2023年，全球急性肌張力不全症市場價值為1.207億美元，預計到2031年將達到1.55億美元，2024年至2031年的年複合成長率（CAGR）預計為3.2%。

圖 1. 2024 年急性肌張力不全症的全球市場佔有率（%），依地區分類

急性肌張力不全症是一種運動障礙，其特徵是不自主的肌肉收縮，導致重複運動和異常姿勢。這些收縮可能會很痛苦，通常是由突然的肌肉痙攣引起的。急性肌肌張力不全症可影響身體的任何部位，包括頸部（頸部肌肌張力不全症）、眼睛（眼肌肌張力不全症）、下巴或舌頭以及四肢。這種症狀有多種原因，包括：

• 藥物引起的肌張力不全症：最常見的原因之一。它可能是某些藥物的副作用，尤其是影響大腦多巴胺途徑的抗精神病藥物。
• 特發性肌張力不全症：原因不明。
• 次發性肌張力不全症：由威爾森氏症、亨丁頓舞蹈症、巴金森氏症、腦損傷或中風等潛在疾病所引起。

市場動態：

全球急性肌肌張力不全症市場是由引起急性肌肌張力不全症的神經系統疾病（如帕金森氏症、腦性麻痹和遲發性）的盛行率上升所推動的。例如，2023年8月9日，世界衛生組織（WHO）發布的一份報告發現，巴金森氏症（PD）是一種導致運動、心理健康、睡眠、疼痛和其他健康問題的腦部疾病。 2021 年，美國有近 100 萬人患有帕金森氏症 (PD)，預計到 2030 年將增加至 120 萬人。帕金森氏症是繼阿茲海默症之後第二常見的神經退化性疾病。

此外，2022年3月，美國國家生物技術資訊中心發布的一份報告發現，美國每年每1,000名兒童中就有2.3至3.6人患有腦性麻痹。痙攣性腦性麻痹最為常見，佔腦性麻痹的61%～76.9%。

本研究的主要特點

• 本報告對全球急性肌張力不全症市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模和年複合成長率（CAGR%）。
• 它還說明了各個細分市場的潛在收益成長機會，並為該市場提供了一系列有吸引力的投資提案。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。
• 它根據公司亮點、產品系列、主要亮點、績效和策略等參數，介紹了全球急性肌肌張力不全症市場的主要企業。
• 該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
• 急性肌張力不全症全球市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進入者和財務分析師。
• 透過用於分析全球急性肌張力不全症市場的各種策略矩陣，將促進相關人員的決策。

目錄

第1章 研究目的與前提

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章市場動態、法規及趨勢分析

• 市場動態
  • 肌張力不全症增加
  • 與藥物相關的副作用
  • 了解不斷變化的治療模式
• 主要亮點
• 監管指引
• 市場趨勢
• PEST分析
• 投資金籌措
• 合併、收購和合作
• 產品映射
• 識別頂級市場參與者
• 市場相關人員採取各種企業發展策略
• 按國家/地區分類的醫療保健支出

第4章全球急性肌張力不全症市場－冠狀病毒（COVID-19）大流行的影響

• 新型冠狀病毒感染疾病（COVID-19）的流行病學
• 供需面分析
• 經濟影響

第5章全球急性肌張力不全症市場，依藥物類別，2019-2031

• 抗膽鹼能藥物
• 苯二氮平類
• 其他（神經毒素等）

第6章 全球急性肌張力不全症市場，依年齡層分類，2019-2031

• 孩子
• 成人

第7章全球急性肌張力不全症市場，按分銷管道，2019-2031

• 醫院藥房
• 零售藥房
• 網路藥房

第8章全球急性肌張力不全症市場，按地區，2019-2031

• 北美洲
• 美國
• 加拿大
• 歐洲
• 德國
• 英國
• 西班牙
• 法國
• 義大利
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 中國
• 印度
• 日本
• 澳洲
• 韓國
• ASEAN
• 其他亞太地區
• 拉丁美洲
• 巴西
• 阿根廷
• 墨西哥
• 其他拉丁美洲
• 中東
• 海灣合作理事會國家
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中部非洲
• 南非

第9章 競爭格局

• 公司簡介
  • Fresenius Kabi
  • Amar Healthcare
  • Johnson &Johnson
  • PAI Pharma
  • Pfizer Inc.
  • Souvin Pharmaceuticals Pvt.Ltd
  • Bayer Healthcare
  • S.Pharmachem
  • Remedy Labs
  • Wan Bury
  • Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.

第10章

• 參考
• 調查方法
• 關於出版商

The global acute dystonia market was valued US$ 120.7 Mn in 2023 and is expected to reach US$ 155.0 Mn by 2031 growing at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.

Figure 1. Global Acute Dystonia Market Share (%), By Region, 2024

Acute dystonia is a movement disorder characterized by involuntary muscle contractions that lead to repetitive movements or abnormal postures. These contractions can be painful and are often caused by a sudden onset of muscle spasms. Acute dystonia can affect any part of the body, including the neck (cervical dystonia), eyes (oculogyric crisis), jaw or tongue, and the limbs. The condition can have varying causes, including:

• Drug-induced Dystonia: One of the most common causes. It can occur as a side effect of certain medications, particularly antipsychotic drugs that affect dopamine pathways in the brain.
• Idiopathic Dystonia: Where the cause is unknown
• Secondary Dystonia: Resulting from an underlying medical condition such as Wilson's disease, Huntington's disease, Parkinson's disease, brain injury, or stroke

Market Dynamics:

The global acute dystonia market is driven by the rising prevalence of neurological disorders that can induce acute dystonia like Parkinson's disease, cerebral palsy, and tardive dyskinesia. For instance, on August 9, 2023, according to a report published by the World Health Organization (WHO), Parkinson's disease (PD) is a brain condition that causes problems with movement, mental health, sleep, pain, and other health issues. Nearly one million people in the U.S. were living with Parkinson's disease (PD) in 2021, while this number is expected to rise to 1.2 million by 2030. Parkinson's disease is the second-most common neurodegenerative disease after Alzheimer's disease.

Furthermore, in March 2022, according to a report published by the National Center for Biotechnology Information, cerebral palsy occurs in 2.3 to 3.6 out of every 1,000 children in the U.S., every year. While spastic cerebral palsy is the most common, making up 61 percent to 76.9 percent of all cerebral palsy cases.

Key Features of the Study:

• This report provides an in-depth analysis of the global acute dystonia market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global acute dystonia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Fresenius Kabi, Amar Healthcare, Johnson & Johnson ,PAI Pharma, Pfizer Inc., Souvin Pharmaceuticals Pvt.Ltd, Bayer Healthcare, S.S.Pharmachem, Remedy Labs, Wan Bury, F. Hoffmann-La Roche Ltd, Bausch Health Companies, Inc., Viatris Inc. , Teva Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global acute dystonia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute dystonia market

Detailed Segmentation:

• Global Acute Dystonia Market, By Drug Class
  • Anticholinergic Agents
  • Benzodiazepines
  • Others (Neurotoxin, etc.)
• Global Acute Dystonia Market, By Age Group
  • Children
  • Adult
• Global Acute Dystonia Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Acute Dystonia Market, By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Top Companies in the Global Acute Dystonia Market:
  • Fresenius Kabi
  • Amar Healthcare
  • Johnson & Johnson
  • PAI Pharma
  • Pfizer Inc.
  • Souvin Pharmaceuticals Pvt.Ltd
  • Bayer Healthcare
  • S.Pharmachem
  • Remedy Labs
  • Wan Bury
  • F.Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Age Group
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of dystonia
  • Side effects associated with drugs
  • Understanding changing treatment patterns
• Key Highlights
• Regulatory Guidelines
• Market Trends
• PEST Analysis
• Investments and Funding
• Mergers, Acquisitions, and Collaborations
• Product Mapping
• Identification of Top Market Players
• Adoption of Various Business Development Strategies by the Market players
• Healthcare Spending by Country

4. Global Acute Dystonia Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Acute Dystonia Market, By Drug Class, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Anticholinergic Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Benzodiazepines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Others (Neurotoxin, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

6. Global Acute Dystonia Market, By Age Group, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Children
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

7. Global Acute Dystonia Market, By Distribution Channel, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

8. Global Acute Dystonia Market, By Region, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020 - 2031
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
• U.S.
• Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
• GCC Countries
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031,(US$ Mn)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Company Profile
  • Fresenius Kabi
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Amar Healthcare
  • Johnson & Johnson
  • PAI Pharma
  • Pfizer Inc.
  • Souvin Pharmaceuticals Pvt.Ltd
  • Bayer Healthcare
  • S.Pharmachem
  • Remedy Labs
  • Wan Bury
  • Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.
• Analyst Views

10. Section

• References
• Research Methodology
• About us